IWEB 0.0004 +100%
EHOS 0.0019 +26%
ERBB 0.0199 +17%
FOGC 0.0003 +200%
Micro-caps outperform large caps and small caps equities. Micro-caps which can be measured by the Russell Microcap Index, have significantly outperformed both the S&P 500 large cap and Russell 2000 small cap indexes over the past five years.
Index Name 5 Years (As of September 27, 2012)
Russell 2000 Index +10.44%
Russell Microcap Index +12.18%
S&P 500 -5.74%
Micro-caps can provide significant diversification to your portfolio. This asset class typically has very low correlations with other U.S. equity classes (as low as 0.60 versus the S&P 500 for the period 1972-2006), as well as low correlations with international equity andfixed-income securities. As Figure 1 shows, however, micro-caps carry higher risks than many other asset classes.
Analyzing Micro Caps Micro-cap companies don’t generate fat investment banking fees for Wall Street firms, so they rarely enjoy regular research coverage by analysts. As a result, it can take more time and effort to analyze a small company than a large one, and fewer published reports means an investor must do more original research. The result, however, is that micro-cap stocks often don’t trade at their full values, creating a price inefficiency from which savvy investors can benefit.
Nano Caps = Is Companies with 50 million dollars and less in market cap valuation
Sources: Google Finance
VANCOUVER, British Columbia and MENLO PARK, Calif., August 29, 2014 /UPTICK Newswire/ — DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar” “the company”) today announced the filing of June 30, 2014 fiscal year-end financial statements. The Company recently changed its fiscal year end to June 30th in order to facilitate an application to list its common stock on a national securities exchange in the timeliest manner possible.
DelMar’s financial statements as filed with the United States Securities Exchange Commission can be viewed on the company’s website at: http://ir.delmarpharma.com/all-sec-filings. The company will host an investor update call to discuss recent highlights and plans for continued advancement of its business plan on Tuesday September 2, 2014 at 10AM PDT / 1PM EDT.
- Dial In: (877) 358-8686 (toll free)
- Passcode: 6043177022
A summary of recent corporate highlights include:
• Promising interim results of DelMar’s ongoing clinical trial with VAL-083 were presented at the annual meetings of both the American Association of Cancer Research (AACR) in April and the American Society of Clinical Oncology (ASCO) in May. Data presented to date demonstrate that VAL-083 is safe and well tolerated at doses up to 40mg/m2. In addition, one of three patients in the 30mg/m2 dose cohort and one of three patients in the 40mg/m2 dose cohort demonstrated stable disease after only one or two cycles of treatment.
• On August 19, DelMar announced the filing of a protocol amendment with the United States Food and Drug Administration to allow enrollment at doses up to 60mg/m2 and that treatment of patients at 50mg/m2has been initiated. DelMar is now delivering higher doses compared to previous glioblastoma clinical trials conducted by the National Cancer Institutes in the United States. The company believes that such higher doses may enhance the potential of VAL-083 to impact a patent’s tumor and improve patient outcomes. Ultimately, DelMar believes advancing to higher doses will increase the chance of success in achieving the longer-term goal to commercialize VAL-083 as a new chemotherapy for glioblastoma patients who have failed, or are unlikely to respond, to currently available treatments.
• DelMar presented new non-clinical research supporting the potential utility of VAL-083 in the treatment of non-small cell lung cancer at AACR in April.
• DelMar received an additional CDN $194,000 nonrefundable funding contribution from that National Research Council of Canada (NRC). Four non-dilutive funding contributions to date from NRC total CDN $327,000 and will be used to support continued non-clinical research aimed at providing competitive differentiation for VAL-083 as a new medicine in the treatment of glioblastoma and other cancers, including non-small cell lung cancer.
• DelMar received gross proceeds of $2,373,937 from the exercise of warrants at $0.65 per warrant that closed on June 6 and an additional $495,448 in gross proceeds from exercise of these warrants under the tender offer which closed on August 8. The exercise of warrants through a private transaction with certain warrant holders and subsequent tender offer has provided the company with additional non-dilutive capital, which the company believes will be sufficient to fund current operations through at least the end of December 2015.
Jeffrey Bacha, president & CEO of DelMar Pharmaceuticals stated, “We are pleased with the overall progress made during the past year in research and development activities. The warrant tender offer and change in our fiscal year end are part of our overall strategy to meet the requirements to list our common stock on a national securities exchange in the most expeditious manner possible. We believe is an important component of executing on our overall mission to increase shareholder value.”
The following tables represent selected financial information as at June 30, 2014 and December 31, 2013. The company’s financial information has been prepared in accordance with US GAAP and this selected information should be read in conjunction with DelMar’s financial statements and Management’s Discussion and Analysis, as filed.
Selected Balance Sheet Data:
|June 30,2014$||December 31,2013$|
|Cash and cash equivalents||4,759,711||4,136,803|
|Total shareholders’ equity (deficiency)||880,479||(817,978)|
Selected Statement of Operations Data (net of share-based payments):
|Six Months ended|
|June 30,2014$||June 30,2013$|
|Research & development net of share-based compensation||848,335||907,223|
|General & administrative net of share-based compensation||1,007,781||1,363,406|
The largest component of research and development expenses are attributable to clinical development costs as the Company continued with its Phase I/II clinical trial with VAL-083 in GBM. The clinical development costs were slightly lower in the current period compared to the prior period due to several factors including timing of patient enrollment and expansion of certain cohorts during 2013. Partially offsetting these items were higher costs in the current period for protocol development as DelMar plans for registration-directed clinical trials with VAL-083. Decrease in general and administrative costs during the current period was largely due to a reduction in professional fees related to activities associated with the company’s reverse take-over and public listing that occurred during 2013.
“Non-cash expenses associated with stock options, shares or warrants issued for services or the changes in the derivative liability associated with certain warrants do not affect our working capital and are influenced by changes in the company’s share price,” stated Mr. Bacha. “We are highlighting expenses net of such charges because this more accurately reflects the operating cash burn associated with our research, drug development and corporate activities. Full details are presented in our financial statements.”
Subsequent to the fiscal year end, DelMar received additional funding through the exercise of warrants for cash. These additional moneys provide working capital sufficient to fund the company’s current operations through at least the end of December, 2015.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company’s lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI) and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action. DelMar’s scientific presentations can be viewed on the company’s website at www.delmarpharma.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
Tampa, FL — (UPTICK Newswire) — 08/29/2014 — UPTICK Newswire interviews CEO & President of Kleangas Energy Technologies Inc.(KGET) Mr. Bo Linton regarding the proceedings of their pellet facility and brand new facility geared mostly towards a new brand of pellets.
In the past six months KGET has started with brokering pellets to several large corporations in mainly Korea also including industries across Europe. By loading pellets into shipping containers in Gardena California the containers are then driven to the Port of Long Beach and from there shipped to Korea. The demand in this pellet industry has been escalating due to the high demand for a cleaner and healthier environment. This fluctuation in KGET’s production has been based toward the Korean coal fire plants/facilities. These facilities are shutting down and the new industries are opening using the pellets to fuel their factories instead of coal making the future cleaner and more efficient. This is good news for KGET because with supply and demand growing business can boom taking the direction for expanding with production and to reach new heights with a new line of product.
Second Cycle Recycling, a subsidiary of KGET, is looking forward to distributing their new pellet production onto the consumer’s shelves and getting a new product into the customer’s home. Based out in Kokomo Indiana, this production will be geared towards producing bedding and fluff pellets for animal bedding, bird bedding and cat littler made from recycled shredded paper and cardboard. Absolutely no chemicals or binding agents are incorporated into the product unlike other litter products that are hard, firm and can cause allergic reactions to pets. This is not a clay based product like the rest of the bedding agents out on the market, it is all recycled paper.
After working on a new kitty litter paper based product for close to a year and a half Mr. Don Willis, Executive Vice President of Kleangas, believes that, “Second Cycle Recycling has produced a more pet friendly and absorbent non-chemical based product that your pets and their paws will love you for.” After sending the finished product to Twin Labs for the safety product testing this new kitty litter is ready to be thrown into full production and will be up and ready to distribute by the beginning of 2015. This fluffy litter’s absorbency is a key factor to the success of its compound more so then the leading clay brands on the market. Its absorbency surface area has been tested against the leading brands of clay based products and shows a result of 3-10 times more absorbent consistency.
Once the standards of the bag design have been approved this product will be produced, bagged and distributed to the consumer’s shelves waiting for the customers to scoop the product off the shelf.
Safe Harbor Statement:
Safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as Kleangas or KGET or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Similarly, statements herein that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
Intelligent Highway Solutions Announces Successful Test of Cannabis Lights and Additional Testing to Produce Greater Yields With New Prototype of Grow Light
SACRAMENTO, Calif., Aug. 28, 2014 UPTICK Newswire — Intelligent Highway Solutions, Inc. (IHSI) is pleased to announce a successful test of its 100 Watt cannabis lighting solution. The light operated with an approximate 80% reduction in energy consumption while running at a temperature of approximately 80 degrees (benefits are less operating cost and acceptable temperature emission, key variables in plant lighting goals). As a result of the successful test, Intelligent Highway is also testing a light, a “prototype,” with three times the power (300 Watts) which will still result in significant energy savings as compared to the existing lighting solutions on the market while still operating at a temperature of approximately 80 degrees. IHS believes adding more lumens and photon density in the new light will produce large yields for Cannabis. The newly designed light should be installed and tested shortly.
Lighting is a very important contributor to the growth of the cannabis plant. Cannabis grown indoors needs 24 hours of strong light for the first 4-6 weeks of the growth cycle. The plants need 2 months of 12.5 hours per day of strong light or more and corresponding hours of complete darkness depending on the plant to flower and ripen. Color of light, amount of lux and heat all affect the growth of the plant and the size of the flower.
FV Pharma International Corp. (FVPI) a Canadian company, which conducted a test on IHSI’s initial lights, advises it is transforming a Canadian factory into a state-of-the-art facility for growing and harvesting medical marijuana. FV Pharma Inc. (Canada), affiliate of FVPI, has applied to Health Canada to become a licensed commercial producer of marijuana under the Government of Canada’s new Marijuana for Medical Purposes Regulations . The company’s application is in the personal security checks stage of the process. If successful, FV Pharma will receive a license to produce marijuana for medical purposes. Thomas Fairfull, Chief Executive Officer of FV Pharma, stated “We are excited to test these new innovative lights and look forward to testing the new more powerful lights that IHSI is developing.”
Devon Jones, Chief Executive Officer of Intelligent Highway Solutions, added, “Each indoor grower of medical marijuana requires a lighting solution to grow healthy, high yielding cannabis plants. Because lighting is such a significant fixed cost for each grower, every grower is searching for a lighting solution which reduces power consumption while growing healthy plants.”
About Intelligent Highway Solutions, Inc.
Intelligent Highway Solutions, Inc. (IHSI) is a technology based electrical contracting company that develops and implements high and low voltage solutions across multiple platforms. Through the development of proprietary wireless vehicle detection systems the company is working to make the nation’s roadways more efficient. IHSI also performs electrical installations, temperature control systems, communication/wireless integration, and advanced lighting systems for commercial applications. In 2014, the Company secured exclusive distribution rights to proprietary lighting solutions directed towards the legal cannabis industry that helps growers reduce costs and improve yields
Forward Looking Statements: Any statements contained herein that are not historical facts are forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended These forward-looking statements are made subject to certain risks and uncertainties, which could cause actual results to differ materially from those presented. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only to the date such information was released. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after release of this information. Only statements from the Company website, filings at sec.gov, and press releases are those of the Company.